Menu
Home
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Misc
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Home
Forums
Labrish
Nyuuz
Zimbabwe to roll out long-acting HIV prevention drug, 46,500 set to benefit
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
[QUOTE="Munyaradzi Mafaro, post: 77124, member: 636"] Zimbabwe is dumping 46,500 people onto Lenacapavir next month, which is this twice-a-year shot that keeps HIV away without needing daily pills. Getrude Ncube from the national prevention crew said they picked districts like Bulawayo, Gweru, and Harare based on where new infections keep spiking, and the health minister announced everything five days after approval came through. The country became the third spot in Africa to greenlight the drug. They are rolling out the injectable to women who struggle with consistent pill schedules, sex workers, and pregnant people in areas where treatment coverage is garbage. The ministry built an AI chatbot called Vimbai that helps people figure out testing and prevention options, and it is already running in Gweru with decent engagement numbers. Survey data showed that awareness of prevention drugs sits under 50 percent, even though oral options have been around since way back, so digital outreach is getting pushed hard before the doses arrive. [/QUOTE]
Insert quotes…
Name
Post reply
Home
Forums
Labrish
Nyuuz
Zimbabwe to roll out long-acting HIV prevention drug, 46,500 set to benefit
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top